@prefix fhir: . @prefix owl: . @prefix rdf: . @prefix rdfs: . @prefix xsd: . # - resource ------------------------------------------------------------------- a fhir:Evidence ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "267243"] ; # fhir:meta [ fhir:versionId [ fhir:v "9" ] ; fhir:lastUpdated [ fhir:v "2025-12-11T20:35:21.032Z"^^xsd:dateTime ] ; fhir:profile ( [ fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"^^xsd:anyURI ; fhir:l ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div [ fhir:v "

Generated Narrative: Evidence 267243

version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en

Profile: NonComparativeEvidence

url: https://fevir.net/resources/Evidence/267243

identifier: FEvIR Object Identifier/267243, FEvIR Linking Identifier/NCT03421379-secondaryOutcomeMeasure-4--OG001

name: NCT03421379_secondaryOutcomeMeasure_4_OG001

title: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379

citeAs:

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267243. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267243. Computable resource at: https://fevir.net/resources/Evidence/267243#json.

\n

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

\n

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

\n

variableDefinition

description:

Glucagon Hydrochloride Solution

\n

note: ,

Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data.

\n

Outcome Measure Denominator Units: Participants

\n

variableRole: Population

observed: A single dose of 1 mg glucagon hydrochloride solution was administered IM (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG001)

variableDefinition

variableRole: Outcome

observed: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration - (NCT03421379)

statistic

statisticType: median

quantity: 0.17 hour (h)

SampleSizes

-KnownDataCount
*68

AttributeEstimates

-TypeRange
*Full Range0.08-0.67 hour (h)
"^^rdf:XMLLiteral ] ] ; # fhir:url [ fhir:v "https://fevir.net/resources/Evidence/267243"^^xsd:anyURI ; fhir:l ] ; # fhir:identifier ( [ fhir:type [ fhir:coding ( [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ; fhir:l ] ; fhir:code [ fhir:v "ACSN" ] ; fhir:display [ fhir:v "Accession ID" ] ] ) ; fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FOI"^^xsd:anyURI ; fhir:l ] ; fhir:value [ fhir:v "267243" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ; fhir:l ] ; fhir:value [ fhir:v "NCT03421379-secondaryOutcomeMeasure-4--OG001" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ) ; # fhir:name [ fhir:v "NCT03421379_secondaryOutcomeMeasure_4_OG001"] ; # fhir:title [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"] ; # fhir:citeAs [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267243. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267243. Computable resource at: https://fevir.net/resources/Evidence/267243#json."] ; # fhir:status [ fhir:v "active"] ; # fhir:author ( [ fhir:name [ fhir:v "Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter" ] ] ) ; # fhir:publisher [ fhir:v "Computable Publishing LLC"] ; # fhir:contact ( [ fhir:telecom ( [ fhir:system [ fhir:v "email" ] ; fhir:value [ fhir:v "support@computablepublishing.com" ] ] ) ] ) ; # fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # fhir:description [ fhir:v "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."] ; # fhir:variableDefinition ( [ fhir:description [ fhir:v "Glucagon Hydrochloride Solution" ] ; fhir:note ( [ fhir:text [ fhir:v "Outcome Measure Population Description: All randomized participants who received at least one dose of study drug and had evaluable PK data." ] ] [ fhir:text [ fhir:v "Outcome Measure Denominator Units: Participants" ] ] ) ; fhir:variableRole [ fhir:v "population" ] ; fhir:observed [ fhir:identifier [ fhir:type [ fhir:text [ fhir:v "ClinicalTrials.gov Outcome Measurement Group Id" ] ] ; fhir:value [ fhir:v "OG001" ] ] ; fhir:display [ fhir:v "A single dose of 1 mg glucagon hydrochloride solution was administered IM" ] ] ] [ fhir:variableRole [ fhir:v "outcome" ] ; fhir:observed [ fhir:l ; fhir:reference [ fhir:v "EvidenceVariable/267231" ] ; fhir:type [ fhir:v "EvidenceVariable"^^xsd:anyURI ; fhir:l fhir:EvidenceVariable ] ; fhir:identifier [ fhir:type [ fhir:text [ fhir:v "FEvIR Linking Identifier" ] ] ; fhir:system [ fhir:v "https://fevir.net/FLI"^^xsd:anyURI ; fhir:l ] ; fhir:value [ fhir:v "NCT03421379-secondaryOutcome-4" ] ; fhir:assigner [ fhir:display [ fhir:v "Computable Publishing LLC" ] ] ] ; fhir:display [ fhir:v "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration - (NCT03421379)" ] ] ] ) ; # fhir:statistic ( [ fhir:statisticType [ fhir:coding ( [ fhir:system [ fhir:v "https://fevir.net/sevco"^^xsd:anyURI ; fhir:l ] ; fhir:code [ fhir:v "STATO:0000574" ] ; fhir:display [ fhir:v "median" ] ] ) ] ; fhir:quantity [ fhir:value [ fhir:v 0.17 ] ; fhir:unit [ fhir:v "hour (h)" ] ] ; fhir:sampleSize [ fhir:knownDataCount [ fhir:v "68"^^xsd:nonNegativeInteger ] ] ; fhir:attributeEstimate ( [ fhir:type [ fhir:text [ fhir:v "Full Range" ] ] ; fhir:range [ fhir:low [ fhir:value [ fhir:v 0.08 ] ; fhir:unit [ fhir:v "hour (h)" ] ] ; fhir:high [ fhir:value [ fhir:v 0.67 ] ; fhir:unit [ fhir:v "hour (h)" ] ] ] ] ) ] ) . # a fhir:Uv . # -------------------------------------------------------------------------------------